Although diffuse large B-cell lymphoma (DLBCL) is curable in elderly patients using standard therapy, according to a study published in Ecancermedicalscience.
Researchers retrospectively evaluated EHRs of 3,087 patients with lymphomas, of which 27% were 65 years of age and older. The median age at disease presentation was 71. Of the population, 212 patients received first line treatment for DLBCL between May 2011 and Dec 2016. The researchers assessed clinical features, co-morbidities, and as well as first line treatment outcomes and hospital costs.
According to the results, patients who received anthracycline-based therapy (n=124) and rituximab-based therapy (n=159) had a median progression free survival (PFS), not reached and 47.0 months compared to 10 months and 7.9 months for patients receiving non-anthracycline and non-rituximab therapies. The researchers noted at a median follow-up of 24 months, the 5-year overall survival and PFS are 44% and 41%, respectively, for the entire cohort.
The researchers concluded: “DLBCL is a curable lymphoma in elderly patients with standard anthracycline and rituximab-based therapies. Improvement in outcomes largely depends on social and financial support to complete the scheduled treatments.”